Forbes January 1, 2026
As health insurers drop coverage of weight loss drugs, access worsens for some who need treatments most. The new direct-to-consumer options offered by manufacturers reduce prices and improve access for a segment of the population that doesn’t have insurance coverage. But for many who are poor or in the lower middle class, spending hundreds of dollars a month on medicines isn’t feasible. Several recently announced Trump administration initiatives could help ease affordability, but much remains uncertain regarding their implementation.
While at least 12% of adults in the United States have been prescribed a glucagon‐like peptide‐1 drug for one or multiple indications, 54% of users report affordability challenges.
As reported by STAT News last month, employers are reducing coverage for obesity...
Today's Sponsors
Today's Sponsor